Newsroom | 35142 results

加州聖卡洛斯--(BUSINESS WIRE)--(美國商業資訊)-- 全球性腫瘤公司BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235)今天公布了2025年第三季的財務業績和公司最新進展。 BeOne共同創辦人、董事長兼執行長John V. Oyler表示：「公司的營收成長表現卓越，資產負債表狀況穩健，這些強勁的財務業績鞏固了我們全球腫瘤學領導者的地位。憑藉長期療效和安全性資料，以及越來越多支援其持續BTK抑制科學假說的證據，BRUKINSA現已成為BTKi類藥物的全球營收領導者。我們的後期血液學產品組合持續推進，其中潛在同類最佳BCL2抑制劑sonrotoclax已展現出令人矚目的臨床結果，而我們的BTK CDAC BGB-16673進一步強化了我們在包括慢性淋巴性白血病(CLL)在內的B細胞惡性腫瘤領域的領先地位。憑藉業界最具潛力的腫瘤學研發產品線之一，我們可望實現多項資料和監管里程碑，進而推動長期價值成長。」 （金額以千美元為單位，未經稽核）     截至9月30日的三個月       截至9月30日的九個月...

SAN CARLOS, California--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), empresa mundial dedicada a la oncología, anunció hoy los resultados financieros y las novedades corporativas del tercer trimestre de 2025. “Estos sólidos resultados financieros refuerzan nuestra posición como líder mundial en oncología, con un crecimiento excepcional de los ingresos y un balance general sólido”, comentó John V. Oyler, cofundador, presidente y director ejecutivo de BeOne. “BRUK...

SAN DIEGO--(BUSINESS WIRE)--Onchilles Pharma Publishes Landmark ELANE Pathway Study and Advances N17350 Toward the Clinic With New Financing and Leading Clinical Advisor...

HOUSTON--(BUSINESS WIRE)--CrossBridge Bio, a biopharmaceutical company pioneering next-generation dual-payload antibody-drug conjugates (ADCs) that have the potential to deliver safer more durable responses in patients, including those resistant to approved ADC therapies, today announced that it has been named the Winner of “Best Drug Developer” at the 2025 World ADC Awards. CrossBridge Bio was selected from a competitive global field by a panel of independent ADC experts and peers. The award r...

LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic imneskibart (AU-007), today presented promising new Phase 2 data from its ongoing study of imneskibart in patients with checkpoint inhibitor (CPI)-refractory melanoma and non-small cell lung cancer (NSCLC). The data were shared in a poster session at the Society for Immunotherapy of Cancer (SITC) 40th Annual M...

HOUSTON & SEATTLE--(BUSINESS WIRE)--Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated immunotherapies for the treatment of cancer and autoimmune diseases, today announced the presentation of data highlighting the clinical activity of IDP-023, the Company’s allogeneic g-NK cell therapy, in patients with relapsed/refractory multiple myeloma. IDP-023 treatment was given as a standalone therapy and in combination with isatuxi...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18 at 2:00 p.m. GMT / 9:00 a.m. ET / 6:00 a.m. PT in London, United Kingdom. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days....

MENLO PARK, Calif.--(BUSINESS WIRE)--Synthekine Inc., an engineered cytokine therapeutics company, today announced positive initial results from a Phase 1a/1b clinical trial of STK-012 in first-line, PD-L1 negative nonsquamous (NSQ) non-small cell lung cancer (NSCLC) in combination with standard of care (SoC) pembrolizumab and chemotherapy (PCT). The data will be presented by Adam J. Schoenfeld, M.D., Memorial Sloan Kettering Cancer Center, New York, as a late-breaking oral presentation at the...

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that our partner, Akeso, Inc. (“Akeso,” HKEX Code: 9926.HK) published results from the Phase III HARMONi-A trial, conducted in China and sponsored by Akeso, featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was presented today as part of the Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2025) in National Harbor, M...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the Phase 3 ASCENT-07 study investigating Trodelvy® (sacituzumab govitecan-hziy) versus chemotherapy as a first-line treatment post-endocrine therapy in HR+/HER2-negative metastatic breast cancer patients did not meet the primary endpoint of progression-free survival (PFS) as assessed by Blinded Independent Central Review (BICR) according to RECIST v1.1 criteria. Overall survival is a key secondary endpoi...